All In Biotech

Free tool

FAERS Monitor: Savella

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022256 or its brand name (Savella, Milnacipran Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

6,009

Serious

2,554

43% of reports

Hospitalization

941

Death reported

156

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea699
  • pain522
  • headache489
  • drug ineffective480
  • vomiting363
  • fatigue347
  • dizziness343
  • insomnia329
  • depression301
  • hyperhidrosis288
  • off label use276
  • anxiety268
  • drug hypersensitivity259
  • rash219
  • arthralgia217

Reports by year received

View as table
YearReports
20043
20055
20064
20075
20087
2009493
2010789
2011586
2012389
2013342
2014304
2015414
2016612
2017375
2018347
2019248
2020251
2021160
2022176
2023139
2024141
2025132
202687

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,150 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperhidrosisSignal2887.87.01,719
drug hypersensitivitySignal2594.74.2754
depressionSignal3014.64.2863
insomniaSignal3294.33.9848
anxietySignal2683.32.9432
nauseaSignal6993.12.91,026
painSignal5223.02.7703
headacheSignal4892.72.5551
vomitingSignal3632.72.4397
dizzinessSignal3432.42.2288
arthralgia2171.81.682
rash2191.81.572
fatigue3471.61.472
drug ineffective4801.31.230
off label use2761.11.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.